Epidemiological, serological and clinical features at baseline (n=549)
| Sex, F/M | 445/104 |
| Age at entry in the registry, years, mean (SD) | 51.9 (±13.6) |
| Age at Raynaud’s onset, years, mean (SD) | 46.5 (±14.3) |
| Age at first non-Raynaud’s feature, years, mean (SD) | 49.8 (±13.7) |
| ANA positive (n, %) | 529 (96.3) |
| Anti-Scl-70 positive (n, %) | 217 (39.5) |
| Anticentromere positive (n, %) | 178 (32.4) |
| Anti-PmScl positive (n, %) | 10 (1.8) |
| Anti-U1RNP positive (n, %) | 10 (1.8) |
| Anti-RNA polymerase III positive (n, %) | 10 (1.8) |
| Limited SSc (n, %) | 370 (67.3) |
| Diffuse SSc (n, %) | 179 (32.6) |
ANA, antinuclear antibody; SSc, systemic sclerosis.